Description

AstraZeneca PLC operates as a prominent biopharmaceutical firm, concentrating its efforts on the entire lifecycle of prescription medications, from their initial discovery and intricate development to large-scale manufacturing and global market introduction. The company's extensive portfolio features a variety of established prescription drugs. Its oncology offerings encompass treatments such as Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For addressing cardiovascular, renal, and metabolic conditions, key therapies include Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. In the respiratory and immunology therapeutic areas, medications like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris are prominent. Furthermore, it addresses rare diseases with specialized therapies such as Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. Beyond these primary categories, AstraZeneca's product lineup extends to critical treatments such as Synagis for respiratory syncytial virus, Fluenz Tetra/FluMist Quadrivalent for influenza, and Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder. Its gastroenterology division features Nexium and Losec/Prilosec, while Vaxzevria and Evusheld serve as treatments for COVID-19. AstraZeneca distributes its pharmaceutical solutions to both primary and specialty care physicians worldwide. This extensive global reach is achieved through a robust network of distributors and local representative offices spanning the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The company actively engages in strategic partnerships, including an agreement with Regeneron Pharmaceuticals, Inc. for the research, development, and commercialization of small molecule obesity treatments. It collaborates with Neurimmune AG on the development and commercialization of NI006. Furthermore, a partnership with Ionis Pharmaceuticals, Inc. focuses on eplontersen, a liver-targeted antisense therapy currently in Phase III trials for transthyretin amyloidosis. AstraZeneca also works alongside Proteros Biostructures GmbH to identify innovative small molecules targeting hematological cancers, and with Sierra Oncology, Inc. to develop and commercialize AZD5153. Historically, the enterprise was known as Zeneca Group PLC, before officially adopting its current designation, AstraZeneca PLC, in April 1999. Established in 1992, the company maintains its corporate headquarters in Cambridge, United Kingdom.